What is CorMedix's fair value adjustment of warrants?

CorMedix (CRMD) reported fair value adjustment of warrants of $3.55M in Q1 2026.

What does fair value adjustment of warrants mean?

Captures the non-cash gain or loss resulting from the periodic revaluation of outstanding warrants issued by the company. As the fair value of these derivative instruments fluctuates based on stock price and volatility, it impacts the company's reported net income. This metric is essential for understanding non-operating earnings volatility.

CorMedix CRMD Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

Emergent BiosolutionsEBS

-$8.4M+11.6%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's fair value adjustment of warrants?: CorMedix (CRMD) reported fair value adjustment of warrants of $3.55M in Q1 2026.
What does fair value adjustment of warrants mean?: Captures the non-cash gain or loss resulting from the periodic revaluation of outstanding warrants issued by the company. As the fair value of these derivative instruments fluctuates based on stock price and volatility, it impacts the company's reported net income. This metric is essential for understanding non-operating earnings volatility.